An artificial intelligence (AI)-enabled platform that can reportedly diagnose heart failure with preserved ejection fraction (HFpEF) through analysis of a single echocardiogram view, the EchoGo Heart Failure now has a HCPCS code for use of the technology in outpatient settings for Medicare beneficiaries.
A newly issued HCPCS code from the Centers for Medicare and Medicaid Services (CMS) may facilitate wider adoption and reimbursement for use of the artificial intelligence (AI)-enabled EchoGo® Heart Failure device (Ultromics) to aid in detecting heart failure with preserved ejection fraction (HFpEF).
Clinicians may utilize the HCPCS code (C9786), which went into effect on July 1, 2023, for “computer-aided detection” of HFpEF based on echocardiography images, according to CMS.1 Ultromics noted the HCPCS code is designated for outpatient use of the EchoGo® Heart Failure device for Medicare beneficiaries.
“This is a major milestone and will enable hospitals to accelerate the adoption of EchoGo Heart Failure to improve detection of HFpEF within their systems,” noted Ross Upton, Ph.D., the CEO and founder of Ultromics. “Given the prevalence of HFpEF, this is a significant development toward recognizing and detecting a heavily underdiagnosed condition.”
EchoGo Heart Failure, which received FDA 510(k) clearance in December 2022, provides automated detection of HFpEF through AI assessment of a single view of an echocardiogram, according to Ultromics.2 The company noted that recently published research has demonstrated an 87.8 percent sensitivity rate and an 83 percent specificity rate for EchoGo Heart Failure in the diagnosis of HFpEF.3,4
References
1. Ultromics. CMS establishes HCPCS code for Ultromics EchoGo Heart Failure, accelerating access to precision HFpEF detection. Available at: https://www.prnewswire.com/news-releases/cms-establishes-hcpcs-code-for-ultromics-echogo-heart-failure-accelerating-access-to-precision-hfpef-detection-301869759.html . Published July 5, 2023. Accessed July 6, 2023.
2. Hall J. FDA clears AI-powered echocardiography platform for detecting heart failure with preserved ejection fraction. Diagnostic Imaging. Available at: https://www.diagnosticimaging.com/view/fda-clears-ai-powered-echocardiography-platform-for-detecting-heart-failure-with-preserved-ejection-fraction . Published December 7, 2022. Accessed July 6, 2023.
3. Nikorowitsch J, Bei der Kellen J, Kirchhof P, et al. Applying the ESC 2016, H2 FPEF, and HFA-PEFF diagnostic algorithms for heart failure with preserved ejection fraction to the general population. ESC Heart Fail. 2021;8(5):3603-3612.
4. Sanders-van Wijk S, Aizpurua AB, Brunner-La Rocca HP, et al. The HFA-PEFF and H2FPEF scores largely disagree in classifying patients with suspected heart failure with preserved ejection fraction. Eur J Heart Fail. 2021;23(5):838-840.
New Study Examines Short-Term Consistency of Large Language Models in Radiology
November 22nd 2024While GPT-4 demonstrated higher overall accuracy than other large language models in answering ACR Diagnostic in Training Exam multiple-choice questions, researchers noted an eight percent decrease in GPT-4’s accuracy rate from the first month to the third month of the study.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
The Reading Room Podcast: Emerging Trends in the Radiology Workforce
February 11th 2022Richard Duszak, MD, and Mina Makary, MD, discuss a number of issues, ranging from demographic trends and NPRPs to physician burnout and medical student recruitment, that figure to impact the radiology workforce now and in the near future.
Ultrasound Device Garners FDA De Novo Nod for Kidney Stone Clearance
November 14th 2024Emerging research demonstrated that the Stone Clear device, which facilitates post-lithotripsy clearance of kidney stone fragments, led to a 70 percent lower risk of relapse in comparison to observation in a control group.